WO2007124757A2 - Use of escitalopram for improving cognition - Google Patents

Use of escitalopram for improving cognition Download PDF

Info

Publication number
WO2007124757A2
WO2007124757A2 PCT/DK2007/050050 DK2007050050W WO2007124757A2 WO 2007124757 A2 WO2007124757 A2 WO 2007124757A2 DK 2007050050 W DK2007050050 W DK 2007050050W WO 2007124757 A2 WO2007124757 A2 WO 2007124757A2
Authority
WO
WIPO (PCT)
Prior art keywords
condition
use according
escitalopram
medicament
unit dose
Prior art date
Application number
PCT/DK2007/050050
Other languages
French (fr)
Other versions
WO2007124757A3 (en
Inventor
Hans Torgny Svensson
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP07722705A priority Critical patent/EP2026793A2/en
Priority to CA002651002A priority patent/CA2651002A1/en
Priority to MX2008013911A priority patent/MX2008013911A/en
Priority to EA200870491A priority patent/EA200870491A1/en
Priority to BRPI0710230-5A priority patent/BRPI0710230A2/en
Priority to AU2007245983A priority patent/AU2007245983A1/en
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Priority to JP2009508134A priority patent/JP2009535367A/en
Publication of WO2007124757A2 publication Critical patent/WO2007124757A2/en
Publication of WO2007124757A3 publication Critical patent/WO2007124757A3/en
Priority to IL194628A priority patent/IL194628A0/en
Priority to ZA2008/08632A priority patent/ZA200808632B/en
Priority to NO20085009A priority patent/NO20085009L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Definitions

  • the present invention relates to the use of the compound escitalopram (INN-name), i.e. (S)- 1 -[3-(dimethylamino)propyl]- 1 -(4-fluorophenyl)-l ,3-dihydro-5- isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
  • escitalopram i.e. (S)- 1 -[3-(dimethylamino)propyl]- 1 -(4-fluorophenyl)-l ,3-dihydro-5- isobenzofurancarbonitrile
  • Escitalopram is the (S)-enantiomer of the following structure:
  • Escitalopram is now marketed as an antidepressant and for the treatment of generalised anxiety disorder (GAD), panic disorder (PD) and social anxiety disorder (SAD).
  • GAD generalised anxiety disorder
  • PD panic disorder
  • SAD social anxiety disorder
  • WO0103694 discloses the use of escitalopram for the treatment of neurotic disorders.
  • ADHD attention deficit hyperactivity disorder
  • Parkinson's disease mild cognitive impairment
  • MCI Alzheimer's Disease
  • Alzheimer's Disease dementia
  • anxiety anxiety
  • age associated memory impairment Alzheimer's Disease or post-traumatic stress disorder
  • patients taking benzodiazepines or tricyclic antidepressants and in a range of neurodegenerative diseases in addition to Parkinson's Disease and Alzheimer's Disease.
  • Diminished cognitive processes refer to the difficulties with attention, learning, memory and executive function (relevant reactions to external stimuli). These can include: deficits in attention, disorganized thinking, slow thinking, difficulty in understanding, poor concentration, impairment of problem solving, poor memory, difficulty in expressing thoughts and/or difficulty in integrating thoughts, feelings and behaviour and extinction of irrelevant thoughts as well as attention and vigilance, verbal learning and memory, visual learning and memory, speed of processing and social cognition.
  • VTA ventral tegmental area
  • fluoxetine, citalopram, paroxetine, sertraline and fluvoxamine all may cause a slight inhibition of the firing rate of mesocorticolimbic dopaminergic neurons in the VTA (Prisco and Eposito, 1995, Br J Pharmacol 116:1923-31; Di Masico et al, 1998, Brain Res Bull 46(6): 547- 54, suggesting that these compounds cannot be used in improving cognitive processes. Moreover it has been reported that citalopram as adjunctive therapy to atypical antipsychotic treatment produces no significant cognitive improvement in patients with schizophrenia (Friedman et al, 2005, J. Clinical Psychopharmacology, 25(3), 237-42).
  • NRI selective noradrenaline reuptake inhibitors
  • reboxetine enhances the excitability of dopaminergic neurons in the VTA with a preferential activation of their burst firing mode (Linner et al, 2001, JPET, 297(2):540-9) and administering of reboxetine has been suggested to have some beneficial effect in the treatment of ADHD.
  • APD atypical, but not typical, antipsychotic drugs
  • Drugs approved for Alzheimer's dementia also have some effect on diminished cognitive processes, but work via completely different mechanisms, reflecting that cognition problems can have very different pathology, such as acetylcholinesterase inhibitors like donepezil, rivastigmine and galantamine.
  • Memantine has weak NMDA antagonistic properties which gives a more "physiological" antagonism of too much background excitation, whereby it increases the signal to noise ratio on glutamate activity.
  • EP 474580 discloses that citalopram is useful in the treatment of cerebrovascular disorders and the brain damage and the impairment of memory functions in connection therewith, and that it shows inhibiting action on platelet aggregation. Furthermore EP 474580 suggests that citalopram has an anti-amnesic effect and improves cognitive function in elderly depressed patients having concomitant dementia. It is mentioned that the optical isomers of the compounds may also be used. The effect mentioned in this disclosure suggests a neuroprotective role. Accordingly there is a significant unmet medical need for therapies, which can improve the cognitive symptoms in various diseases and disorders and/or have lowered side effects as compared to known treatments of cognitive symptoms.
  • Escitalopram has now been found to increase the firing rate of dopamine cells in the VTA, to stimulate the glutamate-driven burst firing in VTA and to facilitate NMDA- induced currents.
  • the present invention relates to the use of escitalopram or a salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
  • the present invention relates the use of escitalopram or a pharmaceutically acceptable salt thereof in combination with one or more antipsychotic agents for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
  • the present invention relates the use of escitalopram or a pharmaceutically acceptable salt thereof for the preparation of a medicament to be used in the adjunct treatment with an antipsychotic agent for improving cognition in a condition where the cognitive processes are diminished.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising escitalopram or a pharmaceutically acceptable salt thereof and one or more antipsychotic compounds for improving cognition in a condition where the cognitive processes are diminished.
  • the present invention relates to a method of improving cognition in a condition where the cognitive processes are diminished comprising administering escitalopram or a pharmaceutically acceptable salt thereof.
  • FIG. 2 Escitalopram stimulates the glutamate-driven burst firing in VTA dopamine cells in vivo more potently than citalopram and R-citalopram blocks the effect of escitalopram.
  • Figure 3 Effect of risperidone (atypical antipsychotic), citalopram, escitalopram, and reboxetine (NRI) on NMDA-induced currents in pyramidal cells of the medial prefrontal cortex in vitro.
  • a novel use of escitalopram or a pharmaceutically acceptable salt thereof, namely for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished is provided.
  • escitalopram increases the firing rate of dopamine cells in the VTA in vivo, an effect blocked by R-citalopram. Additionally it has been found escitalopram compared with citalopram more potently and also dose-dependently stimulates the glutamate-driven burst firing in VTA dopamine cells in vivo, an effect that is blocked by R-citalopram. Moreover it has been found that escitalopram and reboxetine but not citalopram facilitate NMDA-induced currents in pyramidal cells of the medial prefrontal cortex in vitro.
  • the present findings indicate that escitalopram in similarity with NRIs, such as reboxetine, enhance the excitability of the dopaminergic system. Additionally the present findings indicate that escitalopram in similarity with atypical, but not typical antipsychotic drugs, as well as reboxetine facilitates prefrontal glutaminergic neurotransmission.
  • escitalopram can be used for improving cognition in a condition where the cognitive processes are diminished as well as augmenting the response to exposure therapy. Additionally the present findings also strongly suggest escitalopram may be used as adjunct treatment to typical antipsychotic drugs for improving cognition in a condition where the cognitive processes are diminished and in the treatment of schizophrenia and other related diseases and disorders.
  • the phrase "diminished cognitive processes” refers to the difficulties with attention, learning, memory and executive function (relevant reactions to external stimuli). These can include: deficits in attention, disorganized thinking, slow thinking, difficulty in understanding, poor concentration, impairment of problem solving, poor memory, difficulty in expressing thoughts and/or difficulty in integrating thoughts, feelings and behaviour and extinction of irrelevant thoughts as well as attention and vigilance, verbal learning and memory, visual learning and memory, speed of processing and social cognition.
  • One embodiment of the present invention relates to the use of escitalopram or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished wherein the condition is associated with schizophrenia.
  • the condition is associated with Parkinson's Disease.
  • the condition is associated with dementia, such as AIDS dementia.
  • the condition is associated with an anxiety disorder.
  • the condition is associated with age associated memory impairment.
  • the condition is associated with depression, including major depression, in particular in elderly.
  • the condition is associated with the use of benzodiazepines.
  • the condition is associated with the use of tricyclic antidepressants.
  • the condition is associated with Alzheimer's Disease. In another embodiment of the invention the condition is associated with attention deficit hyperactivity disorder (ADHD). In another embodiment of the invention the condition is associated with post-traumatic stress disorder (PTSD).
  • the medicament is for administration as a unit dose. In further embodiment of the invention the unit dose is containing escitalopram in an amount from 1.0 mg to 50 mg, more preferred 5 mg/day to 20 mg/day, most preferably 10 mg. In a further embodiment the unit dose is given once daily. In a further embodiment the daily doses are, 5, 10 or 20 mg.
  • Another embodiment of the present invention relates to the use of escitalopram or a pharmaceutically acceptable salt thereof in combination with one or more antipsychotic compounds for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished wherein the condition is associated with schizophrenia.
  • the condition is associated with Parkinson's Disease.
  • the condition is associated with dementia, such as AIDS dementia.
  • the condition is associated with an anxiety disorder.
  • the condition is associated with age associated memory impairment.
  • the condition is associated with depression, including major depression, in particular in elderly.
  • the condition is associated with the use of benzodiazepines.
  • condition is associated with the use of tricyclic antidepressants.
  • condition is associated with Alzheimer's Disease.
  • condition is associated with attention deficit hyperactivity disorder (ADHD).
  • ADHD attention deficit hyperactivity disorder
  • condition is associated with post-traumatic stress disorder (PTSD).
  • antipsychotic compound is a compound approved for the treatment of a psychotic condition.
  • the antipsychotic compound is selected from the list of Asenapine, Blonanserin, Iloperidone, Paliperidone, Bifeprunox, Lurasidone, Ocaperidone, Talnetant, ACP 104, SLV 310, ACR 16, YKP 1358, GW 773812, RGH 188, SLV 314, Y-931, BL 1020, Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Trifiupromazine, Cyamemazine, Chlorproethazine, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Haloperidol, Trifluperidol,
  • a further embodiment of the present invention relates to the use of escitalopram or a pharmaceutically acceptable salt thereof for the preparation of a medicament to be used in the adjunct treatment with an antipsychotic compound for improving cognition in a condition where the cognitive processes are diminished wherein the condition is associated with schizophrenia.
  • the condition is associated with Parkinson's Disease.
  • the condition is associated with dementia, such as AIDS dementia.
  • the condition is associated with an anxiety disorder.
  • the condition is associated with age associated memory impairment.
  • the condition is associated with depression, including major depression, in particular in elderly.
  • the condition is associated with the use of benzodiazepines.
  • condition is associated with the use of tricyclic antidepressants.
  • condition is associated with Alzheimer's Disease.
  • condition is associated with attention deficit hyperactivity disorder (ADHD).
  • ADHD attention deficit hyperactivity disorder
  • condition is associated with post-traumatic stress disorder (PTSD).
  • antipsychotic compound is a compound approved for the treatment of a psychotic condition.
  • the antipsychotic agent is selected from the list of Asenapine, Blonanserin, Iloperidone, Paliperidone, Bifeprunox, Lurasidone, Ocaperidone, Talnetant, ACP 104, SLV 310, ACR 16, YKP 1358, GW 773812, RGH 188, SLV 314, Y-931, BL 1020, Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Triflupromazine, Cyamemazine, Chlorproethazine, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Haloperidol, Trifluperidol, Melper
  • a further embodiment of the present invention relates to a method of improving cognition in a condition where the cognitive processes are diminished comprising administering escitalopram or a pharmaceutically acceptable salt thereof wherein the condition is associated with schizophrenia.
  • the condition is associated with Parkinson's Disease.
  • the condition is associated with dementia, such as AIDS dementia.
  • the condition is associated with an anxiety disorder.
  • the condition is associated with age associated memory impairment.
  • the condition is associated with depression, including major depression, in particular in elderly.
  • the condition is associated with the use of benzodiazepines.
  • the condition is associated with the use of tricyclic antidepressants.
  • the condition is associated with Alzheimer's Disease.
  • the condition is associated with attention deficit hyperactivity disorder (ADHD).
  • PTSD post-traumatic stress disorder
  • a further embodiment of the present invention relates to the use of escitalopram for the preparation of a medicament for the treatment of schizophrenia wherein the negative and cognitive symptoms are improved.
  • a further embodiment of the present invention relates to the use of escitalopram for the preparation of a medicament for the treatment of attention deficit hyperactivity disorder (ADHD).
  • ADHD attention deficit hyperactivity disorder
  • escitalopram the facilitation of the glutamatergic neurotransmission in prefrontal cortex, likely means that escitalopram can be used to enhance the effect of psychotherapy, e.g. exposure-based therapies.
  • Escitalopram could affect anxiety disorders, both directly through the SRI component and through facilitation of e.g. extinction processes during psychotherapy.
  • a further embodiment of the present invention relates to the use of escitalopram for the preparation of a medicament useful in facilitating psychotherapy, cognitive behavioural therapy and exposure -based therapy.
  • the present invention thus provides a significant improvement in the treatment of cognition in conditions where the cognitive processes are diminished.
  • the advantages of the invention, compared to known treatments are better efficacy and potentionally lowered side-effects.
  • some patients groups that could not be treated at all before might, by the use of escitalopram according to the present invention, experience improved effects on cognitive processes.
  • escitalopram or a pharmaceutically acceptable salt thereof may be administered in any suitable way e.g. orally or parenterally, and it may be presented in any suitable form for such administration, e.g. in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection.
  • the compound of the invention is administered in the form of a solid pharmaceutical entity, suitably as a tablet or a capsule or in the form of a suspension, solution or dispersion for injection.
  • Tablets may thus be prepared by mixing the active ingredients with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a convenient tabletting machine.
  • adjuvants or diluents comprise: corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive such as colourings, flavourings, preservatives, etc. may also be used provided that they are compatible with the active ingredients.
  • Escitalopram is preferably used in the form of the oxalate salt thereof, escitalopram as the base or as the HBr salt or the likes or any other pharmaceutically acceptable salt thereof could also be used.
  • Escitalopram is most conveniently administered orally in unit dosage forms such as tablets or capsules, containing the active ingredient in a dose from about 1.0 mg to 50 mg, more preferred 5 mg/day to 20 mg/day, most preferably 10 mg. Such a unit dose is preferably given once daily. Preferred daily doses are, 5, 10 or 20 mg.
  • oxalate of escitalopram may be prepared as described in US Patent No 4,943,590 and the base and other pharmaceutically acceptable salts may be obtained from the base by standard procedures.
  • the acid addition salts used according to the invention may be obtained by treatment of escitalopram with the acid in an inert solvent followed by precipitation, isolation and optionally re-crystallisation by known methods and if desired micronisation of the crystalline product by wet or dry milling or another convenient process, or preparation of particles from a solvent-emulsification process.
  • the amount of the above-mentioned compounds actually administered will be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
  • Electrodes were pulled in a Narishige vertical puller from borosilicate glass capillaries with outer and inner diameters of 1.50 and 1.17 mm, respectively, and filled with 2% Pontamine Sky Blue in 2 M NaCl.
  • the electrodes were broken under microscope to yield an impedance of 2-4 M ⁇ at 135 Hz and then slowly lowered into a hole drilled in the skull above the VTA (3.2 ⁇ 0.3 mm anterior of the interaural line and 0.7 ⁇ 0.2 mm lateral to the midline by using a hydraulic microdrive.
  • Extracellular electrical activity was amplified, filtered (band pass 0.3-3 kHz), discriminated and monitored on an oscilloscope and an audiomonitor.
  • Discriminated spikes were fed via a CED 1401 interface to a computer running CED Spike 2 software. After the experiment the recording site was marked by iontophoresis of Pontamine Sky Blue into the tissue. The rat was killed with an overdose of anesthetic, and the brain was removed and placed in 25% sucrose 10% paraformaldehyde solution. Sections of the VTA were cut (50 ⁇ M) and stained with Neutral Red and the recording sites were verified by light microscopy.
  • a single slice containing mPFC was then transferred to a recording chamber (32 0 C), in which it was held submerged in-between two nylon nets.
  • the chamber was continuously perfused by aerated Ringer's solution at a flow rate of 2 ml/min.
  • Standard intracellular and single-electrode voltage-clamp techniques were used to record pyramidal cells in layers V and VI of the mPFC in slice preparations as described previously. Briefly, electrodes were pulled from borosilicate glass capillaries by using a horizontal electrode puller. Recording electrodes were filled with 2 M Potassium Acetate (the tip resistance was between 20 and 160 M ⁇ ) and used for recording the mPFC neurons with an Axoclamp 2A amplifier.
  • Single electrode voltage-clamp (holding potential - 60 mV) was performed in the discontinuous mode with a sampling rate of 5-6.2 kHz.
  • the voltage recordings were acquired using a digital/analogue sampling and acquisition software.
  • glycine (1 ⁇ M,to enhance the NMDA-induced responses
  • bicucculine 5 ⁇ M,to block the ⁇ - aminobutyric acid type A (GABA A ) responses
  • GABA A ⁇ - aminobutyric acid type A
  • the effects of the drugs or drug combinations on the NMDA-induced currents were calculated by dividing the NMDA-induced currents after the bath application of the drugs by the control NMDA-induced currents. The results shown in the figure are presented as mean ⁇ S.E.M.
  • Figure 1 describes the effect of citalopram and each of its enantiomers on firing rate of dopamine cells in the VTA. It is shown that citalopram at the tested doses (0-1280 ⁇ g/kg) does not increase the firing rate. On the other hand escitalopram elevates firing rate statistically significant at 320 ⁇ g/kg and this effect appears to be maintained at the higher dose (640 ⁇ g/kg). Furthermore it is shown that the firing rate is unaffected by R-citalopram and that the effect of escitalopram (320 ⁇ g/kg) can be blocked by pre-treatment with 320 ⁇ g/kg of R-citalopram, thus further substantiating that this effect is specific to escitalopram.
  • Figure 2 describes the effect of citalopram and each of its enantiomers on burst firing of the dopaminergic cells recorded in the in the VTA. It was shown that escitalopram increases burst firing statistically significant dose-dependently at doses equal to and above 160 ⁇ g/kg. At the highest dose tested (640 ⁇ g/kg) escitalopram causes a burst difference of about 20%. Citalopram also appear to increase burst firing, allthough this only reaches significance at the 640 ⁇ g/kg dose, and the maximal response appears to be approximately 10% burst difference. Further it is shown that R- citalopram alone has no effect on burst firing and that R-citalopram (320 ⁇ g/kg) significantly inhibits the effect of escitalopram (320 ⁇ g/kg).
  • Figure 3 describes the effect of risperidone (atypical antipsychotic), citalopram, escitalopram and reboxetine (NRI) on NMDA-induced currents in pyramidal cells of the prefrontal cortex. It has previously been shown that atypical antipsychotics increase NMDA-induced currents in this preparation. This is examplified by risperidone. It is shown that reboxetine (NRI) but not citalopram (SSRI), nor fluoxetine (data not shown) increases NMDA-induced currents. Surprisingly escitalopram facilitates the NMDA-induced currents to similar extent as the risperidone and reboxetine. It is furthermore shown that this effect is likely mediated through the dopamine Dl receptor as a dopamine Dl receptor antagonist (SCH 23390) reverses the effect of escitalopram.
  • SCH 23390 dopamine Dl receptor antagonist

Abstract

The present invention relates to the use of the compound escitalopram (INN-name), i.e. (S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5- isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.

Description

New uses of escitalopram
The present invention relates to the use of the compound escitalopram (INN-name), i.e. (S)- 1 -[3-(dimethylamino)propyl]- 1 -(4-fluorophenyl)-l ,3-dihydro-5- isobenzofurancarbonitrile, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
Background of the Invention
Escitalopram is the (S)-enantiomer of the following structure:
Figure imgf000002_0001
Formula I
The compound and a method for its preparation are disclosed in US Patent No 4,943,590. It is a selective, centrally acting serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor, accordingly having antidepressant activities. The antidepressant activity and fast onset of action of the compound has e.g. been reported in Montgomery SA, et al Pharmacol Toxicol (2001) 88: 282-286.
Escitalopram is now marketed as an antidepressant and for the treatment of generalised anxiety disorder (GAD), panic disorder (PD) and social anxiety disorder (SAD).
WO0103694 discloses the use of escitalopram for the treatment of neurotic disorders.
Sanchez et al, 2004, Psychopharmacology, 174, 163-176, discloses data regarding the inhibition of the effects of escitalopram by R-citalopram and suggests that the better clinical effect observed for escitalopram versus citalopram is due to the removal of this inhibition.
Diminished cognitive processes can be experienced in several patient groups, e.g. by schizophrenic, depressive or psychotic patients and patients with attention deficit hyperactivity disorder (ADHD), Parkinson's disease, mild cognitive impairment
(MCI), dementia, anxiety, age associated memory impairment, Alzheimer's Disease or post-traumatic stress disorder and patients taking benzodiazepines or tricyclic antidepressants and in a range of neurodegenerative diseases in addition to Parkinson's Disease and Alzheimer's Disease.
Diminished cognitive processes refer to the difficulties with attention, learning, memory and executive function (relevant reactions to external stimuli). These can include: deficits in attention, disorganized thinking, slow thinking, difficulty in understanding, poor concentration, impairment of problem solving, poor memory, difficulty in expressing thoughts and/or difficulty in integrating thoughts, feelings and behaviour and extinction of irrelevant thoughts as well as attention and vigilance, verbal learning and memory, visual learning and memory, speed of processing and social cognition.
Previous studies have shown that an increase in activity of dopamine neurons in the ventral tegmental area (VTA), in particular in burst firing, appear to selectively increase dopamine release in the medial prefrontal cortex. Dopamine in this brain region has been shown to play an important role in the modulation of some cognitive functions, e.g. working memory, through enhancement of glutamate function. Preclinical studies demonstrate that several SSRFs, i.e. fluoxetine, citalopram, paroxetine, sertraline and fluvoxamine all may cause a slight inhibition of the firing rate of mesocorticolimbic dopaminergic neurons in the VTA (Prisco and Eposito, 1995, Br J Pharmacol 116:1923-31; Di Masico et al, 1998, Brain Res Bull 46(6): 547- 54, suggesting that these compounds cannot be used in improving cognitive processes. Moreover it has been reported that citalopram as adjunctive therapy to atypical antipsychotic treatment produces no significant cognitive improvement in patients with schizophrenia (Friedman et al, 2005, J. Clinical Psychopharmacology, 25(3), 237-42). In contrast, the selective noradrenaline reuptake inhibitors (NRI), such as reboxetine enhances the excitability of dopaminergic neurons in the VTA with a preferential activation of their burst firing mode (Linner et al, 2001, JPET, 297(2):540-9) and administering of reboxetine has been suggested to have some beneficial effect in the treatment of ADHD.
The cognitive-enhancing effects of atypical, but not typical, antipsychotic drugs (APD 's) have been ascribed to increased dopamine function and facilitation glutamatergic neurotransmission in the prefrontal cortical (as demonstrated by enhancement of NMDA receptor function; Ninan et al., 2003, Synapse, 48(2), 66-79).
Diminished cognitive processes in schizophrenia can to a certain extend be treated with atypical antipsychotics, however in general the effects of present antipsychotics on cognition are relatively modest, allthough the 2nd generation (=atypical) antipsychotics have some effect (risperidone, olanzapine, clozapine, quetiapine, sertindole). Drugs approved for Alzheimer's dementia also have some effect on diminished cognitive processes, but work via completely different mechanisms, reflecting that cognition problems can have very different pathology, such as acetylcholinesterase inhibitors like donepezil, rivastigmine and galantamine. Memantine has weak NMDA antagonistic properties which gives a more "physiological" antagonism of too much background excitation, whereby it increases the signal to noise ratio on glutamate activity.
EP 474580 discloses that citalopram is useful in the treatment of cerebrovascular disorders and the brain damage and the impairment of memory functions in connection therewith, and that it shows inhibiting action on platelet aggregation. Furthermore EP 474580 suggests that citalopram has an anti-amnesic effect and improves cognitive function in elderly depressed patients having concomitant dementia. It is mentioned that the optical isomers of the compounds may also be used. The effect mentioned in this disclosure suggests a neuroprotective role. Accordingly there is a significant unmet medical need for therapies, which can improve the cognitive symptoms in various diseases and disorders and/or have lowered side effects as compared to known treatments of cognitive symptoms.
Escitalopram has now been found to increase the firing rate of dopamine cells in the VTA, to stimulate the glutamate-driven burst firing in VTA and to facilitate NMDA- induced currents.
Summary of the Invention
In a first aspect the present invention relates to the use of escitalopram or a salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
In a second aspect the present invention relates the use of escitalopram or a pharmaceutically acceptable salt thereof in combination with one or more antipsychotic agents for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
In a third aspect the present invention relates the use of escitalopram or a pharmaceutically acceptable salt thereof for the preparation of a medicament to be used in the adjunct treatment with an antipsychotic agent for improving cognition in a condition where the cognitive processes are diminished.
In a fourth aspect the present invention relates to a pharmaceutical composition comprising escitalopram or a pharmaceutically acceptable salt thereof and one or more antipsychotic compounds for improving cognition in a condition where the cognitive processes are diminished.
In a sixth aspect the present invention relates to a method of improving cognition in a condition where the cognitive processes are diminished comprising administering escitalopram or a pharmaceutically acceptable salt thereof. Brief description of the drawings
Figure 1 : Escitalopram increases the firing rate of dopamine cells in the VTA in vivo and R-citalopram blocks the effect of escitalopram.
Figure 2: Escitalopram stimulates the glutamate-driven burst firing in VTA dopamine cells in vivo more potently than citalopram and R-citalopram blocks the effect of escitalopram. Figure 3: Effect of risperidone (atypical antipsychotic), citalopram, escitalopram, and reboxetine (NRI) on NMDA-induced currents in pyramidal cells of the medial prefrontal cortex in vitro.
Detailed description of the Invention
According to the present invention, a novel use of escitalopram or a pharmaceutically acceptable salt thereof, namely for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished is provided.
It has now been found that escitalopram increases the firing rate of dopamine cells in the VTA in vivo, an effect blocked by R-citalopram. Additionally it has been found escitalopram compared with citalopram more potently and also dose-dependently stimulates the glutamate-driven burst firing in VTA dopamine cells in vivo, an effect that is blocked by R-citalopram. Moreover it has been found that escitalopram and reboxetine but not citalopram facilitate NMDA-induced currents in pyramidal cells of the medial prefrontal cortex in vitro.
The present findings indicate that escitalopram in similarity with NRIs, such as reboxetine, enhance the excitability of the dopaminergic system. Additionally the present findings indicate that escitalopram in similarity with atypical, but not typical antipsychotic drugs, as well as reboxetine facilitates prefrontal glutaminergic neurotransmission.
These effects strongly suggest that escitalopram can be used for improving cognition in a condition where the cognitive processes are diminished as well as augmenting the response to exposure therapy. Additionally the present findings also strongly suggest escitalopram may be used as adjunct treatment to typical antipsychotic drugs for improving cognition in a condition where the cognitive processes are diminished and in the treatment of schizophrenia and other related diseases and disorders.
The phrase "diminished cognitive processes" refers to the difficulties with attention, learning, memory and executive function (relevant reactions to external stimuli). These can include: deficits in attention, disorganized thinking, slow thinking, difficulty in understanding, poor concentration, impairment of problem solving, poor memory, difficulty in expressing thoughts and/or difficulty in integrating thoughts, feelings and behaviour and extinction of irrelevant thoughts as well as attention and vigilance, verbal learning and memory, visual learning and memory, speed of processing and social cognition.
One embodiment of the present invention relates to the use of escitalopram or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished wherein the condition is associated with schizophrenia. In another embodiment of the invention the condition is associated with Parkinson's Disease. In another embodiment of the invention the condition is associated with dementia, such as AIDS dementia. In another embodiment of the invention the condition is associated with an anxiety disorder. In another embodiment of the invention the condition is associated with age associated memory impairment. In another embodiment of the invention the condition is associated with depression, including major depression, in particular in elderly. In another embodiment of the invention the condition is associated with the use of benzodiazepines. In another embodiment of the invention the condition is associated with the use of tricyclic antidepressants. In another embodiment of the invention the condition is associated with Alzheimer's Disease. In another embodiment of the invention the condition is associated with attention deficit hyperactivity disorder (ADHD). In another embodiment of the invention the condition is associated with post-traumatic stress disorder (PTSD). In a further embodiment of the invention the medicament is for administration as a unit dose. In further embodiment of the invention the unit dose is containing escitalopram in an amount from 1.0 mg to 50 mg, more preferred 5 mg/day to 20 mg/day, most preferably 10 mg. In a further embodiment the unit dose is given once daily. In a further embodiment the daily doses are, 5, 10 or 20 mg.
Another embodiment of the present invention relates to the use of escitalopram or a pharmaceutically acceptable salt thereof in combination with one or more antipsychotic compounds for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished wherein the condition is associated with schizophrenia. In another embodiment of the invention the condition is associated with Parkinson's Disease. In another embodiment of the invention the condition is associated with dementia, such as AIDS dementia. In another embodiment of the invention the condition is associated with an anxiety disorder. In another embodiment of the invention the condition is associated with age associated memory impairment. In another embodiment of the invention the condition is associated with depression, including major depression, in particular in elderly. In another embodiment of the invention the condition is associated with the use of benzodiazepines. In another embodiment of the invention the condition is associated with the use of tricyclic antidepressants. In another embodiment of the invention the condition is associated with Alzheimer's Disease. In another embodiment of the invention the condition is associated with attention deficit hyperactivity disorder (ADHD). In another embodiment of the invention the condition is associated with post-traumatic stress disorder (PTSD). In another embodiment of the invention the antipsychotic compound is a compound approved for the treatment of a psychotic condition. In a further embodiment of the invention the antipsychotic compound is selected from the list of Asenapine, Blonanserin, Iloperidone, Paliperidone, Bifeprunox, Lurasidone, Ocaperidone, Talnetant, ACP 104, SLV 310, ACR 16, YKP 1358, GW 773812, RGH 188, SLV 314, Y-931, BL 1020, Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Trifiupromazine, Cyamemazine, Chlorproethazine, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Haloperidol, Trifluperidol, Melperone, Moperone, Pipamperone, Bromperidol, Benperidol, Droperidol, Fluanisone, Oxypertine, Molindone, Sertindole, Ziprasidone, Flupentixol, Clopenthixol, Chlorprothixene, Tiotixene, Zuclopenthixol, Fluspirilene, Pimozide, Penfluridol, Loxapine, Clozapine, Olanzapine, Quetiapine, Sulpiride, Sultopride, Tiapride, Remoxipride, Amisulpride, Veralipride, Levosulpiride, Prothipendyl, Risperidone, Clotiapine, Mosapramine, Zotepine and Aripiprazole.
A further embodiment of the present invention relates to the use of escitalopram or a pharmaceutically acceptable salt thereof for the preparation of a medicament to be used in the adjunct treatment with an antipsychotic compound for improving cognition in a condition where the cognitive processes are diminished wherein the condition is associated with schizophrenia. In another embodiment of the invention the condition is associated with Parkinson's Disease. In another embodiment of the invention the condition is associated with dementia, such as AIDS dementia. In another embodiment of the invention the condition is associated with an anxiety disorder. In another embodiment of the invention the condition is associated with age associated memory impairment. In another embodiment of the invention the condition is associated with depression, including major depression, in particular in elderly. In another embodiment of the invention the condition is associated with the use of benzodiazepines. In another embodiment of the invention the condition is associated with the use of tricyclic antidepressants. In another embodiment of the invention the condition is associated with Alzheimer's Disease. In another embodiment of the invention the condition is associated with attention deficit hyperactivity disorder (ADHD). In another embodiment of the invention the condition is associated with post-traumatic stress disorder (PTSD). In another embodiment of the invention the antipsychotic compound is a compound approved for the treatment of a psychotic condition. In a further embodiment of the invention the antipsychotic agent is selected from the list of Asenapine, Blonanserin, Iloperidone, Paliperidone, Bifeprunox, Lurasidone, Ocaperidone, Talnetant, ACP 104, SLV 310, ACR 16, YKP 1358, GW 773812, RGH 188, SLV 314, Y-931, BL 1020, Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Triflupromazine, Cyamemazine, Chlorproethazine, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Haloperidol, Trifluperidol, Melperone, Moperone, Pipamperone, Bromperidol, Benperidol, Droperidol, Fluanisone, Oxypertine, Molindone, Sertindole, Ziprasidone, Flupentixol, Clopenthixol, Chlorprothixene, Tiotixene, Zuclopenthixol, Fluspirilene, Pimozide, Penfluridol, Loxapine, Clozapine, Olanzapine, Quetiapine, Sulpiride, Sultopride, Tiapride, Remoxipride, Amisulpride, Veralipride, Levosulpiride, Prothipendyl, Risperidone, Clotiapine, Mosapramine, Zotepine and Aripiprazole.
A further embodiment of the present invention relates to a method of improving cognition in a condition where the cognitive processes are diminished comprising administering escitalopram or a pharmaceutically acceptable salt thereof wherein the condition is associated with schizophrenia. In another embodiment of the invention the condition is associated with Parkinson's Disease. In another embodiment of the invention the condition is associated with dementia, such as AIDS dementia. In another embodiment of the invention the condition is associated with an anxiety disorder. In another embodiment of the invention the condition is associated with age associated memory impairment. In another embodiment of the invention the condition is associated with depression, including major depression, in particular in elderly. In another embodiment of the invention the condition is associated with the use of benzodiazepines. In another embodiment of the invention the condition is associated with the use of tricyclic antidepressants. In another embodiment of the invention the condition is associated with Alzheimer's Disease. In another embodiment of the invention the condition is associated with attention deficit hyperactivity disorder (ADHD). In another embodiment of the invention the condition is associated with post-traumatic stress disorder (PTSD).
A further embodiment of the present invention relates to the use of escitalopram for the preparation of a medicament for the treatment of schizophrenia wherein the negative and cognitive symptoms are improved.
A further embodiment of the present invention relates to the use of escitalopram for the preparation of a medicament for the treatment of attention deficit hyperactivity disorder (ADHD).
Increasing glutamatergic neurotransmission pharmacologically have been shown to be usefull in enhancing the effect of exposure-based therapy which is likely transferable to other cognitive behavioural therapies (Augmentation of exposure therapy with D- cycloserine for social anxiety disorder, Arch Gen Psychiatry, vol 63, 298-304; Pharmacological Treatments that Facilitate Extinction of Fear: Relevance to Psychotherapy, The journal of American society for experimental neurotherapeutics, vol. 3, 82-96; Ressler et al, Arch Gen Psychiatry, 2004, 61(11): 1136-44. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear). Thus for escitalopram, the facilitation of the glutamatergic neurotransmission in prefrontal cortex, likely means that escitalopram can be used to enhance the effect of psychotherapy, e.g. exposure-based therapies. Escitalopram could affect anxiety disorders, both directly through the SRI component and through facilitation of e.g. extinction processes during psychotherapy.
Thus a further embodiment of the present invention relates to the use of escitalopram for the preparation of a medicament useful in facilitating psychotherapy, cognitive behavioural therapy and exposure -based therapy.
The present invention thus provides a significant improvement in the treatment of cognition in conditions where the cognitive processes are diminished. The advantages of the invention, compared to known treatments are better efficacy and potentionally lowered side-effects. Moreover some patients groups that could not be treated at all before might, by the use of escitalopram according to the present invention, experience improved effects on cognitive processes.
According to the invention, escitalopram or a pharmaceutically acceptable salt thereof may be administered in any suitable way e.g. orally or parenterally, and it may be presented in any suitable form for such administration, e.g. in the form of tablets, capsules, powders, syrups or solutions or dispersions for injection. Preferably, and in accordance with the purpose of the present invention, the compound of the invention is administered in the form of a solid pharmaceutical entity, suitably as a tablet or a capsule or in the form of a suspension, solution or dispersion for injection.
Methods for the preparation of solid pharmaceutical preparations are well known in the art. Tablets may thus be prepared by mixing the active ingredients with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a convenient tabletting machine. Examples of adjuvants or diluents comprise: corn starch, lactose, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive such as colourings, flavourings, preservatives, etc. may also be used provided that they are compatible with the active ingredients.
Escitalopram is preferably used in the form of the oxalate salt thereof, escitalopram as the base or as the HBr salt or the likes or any other pharmaceutically acceptable salt thereof could also be used.
Escitalopram is most conveniently administered orally in unit dosage forms such as tablets or capsules, containing the active ingredient in a dose from about 1.0 mg to 50 mg, more preferred 5 mg/day to 20 mg/day, most preferably 10 mg. Such a unit dose is preferably given once daily. Preferred daily doses are, 5, 10 or 20 mg.
The oxalate of escitalopram may be prepared as described in US Patent No 4,943,590 and the base and other pharmaceutically acceptable salts may be obtained from the base by standard procedures.
Thus the acid addition salts used according to the invention may be obtained by treatment of escitalopram with the acid in an inert solvent followed by precipitation, isolation and optionally re-crystallisation by known methods and if desired micronisation of the crystalline product by wet or dry milling or another convenient process, or preparation of particles from a solvent-emulsification process.
The antipsychotic compounds that can be used according to the present invention is preferably selected from the list of Asenapine, Blonanserin, Iloperidone,
Paliperidone, Bifeprunox, Lurasidone, Ocaperidone, Talnetant, ACP 104, SLV 310, ACR 16, YKP 1358, GW 773812, RGH 188, SLV 314, Y-931, BL 1020, Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Triflupromazine, Cyamemazine, Chlorproethazine, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Haloperidol, Trifluperidol, Melperone, Moperone, Pipamperone, Bromperidol, Benperidol, Droperidol, Fluanisone, Oxypertine, Molindone, Sertindole, Ziprasidone, Flupentixol, Clopenthixol, Chlorprothixene, Tiotixene, Zuclopenthixol, Fluspirilene, Pimozide, Penfluridol, Loxapine, Clozapine, Olanzapine, Quetiapine, Sulpiride, Sultopride, Tiapride, Remoxipride, Amisulpride, Veralipride, Levosulpiride, Prothipendyl, Risperidone, Clotiapine, Mosapramine, Zotepine and Aripiprazole. In particular, Risperidone, Olanzapine, Clozapine, Quetiapine, Sertindole, Ocaperidone, Iloperidone, BL 1020, YKP1358, Ziprasidone, Paliperidone, Asenopine, Lurasidone, Aripripazol and Bifeprunox. According to the present invention these antipsychotic compounds should be administered in their respectively clinically approved doses, such as approved by the FDA and/or EMEA. However, it will be understood that the amount of the above-mentioned compounds actually administered will be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
Experimentals
In vivo assessment of dopamine neuron firing in rat ventral tegmental area was conducted as described by Schilstrom et al. (Neuroscience 125:957-64, 2004). Briefly, male Sprague Dawley rats (250-300 g) were anesthetized with chloral hydrate (400 mg/kg i.p.) and mounted in a stereotactic frame. Anesthesia was maintained throughout the experiment with periodical injections of chloral hydrate and body temperature was kept at 37 0C with a rectal thermometer connected to an electrical heating pad. Recording electrodes were pulled in a Narishige vertical puller from borosilicate glass capillaries with outer and inner diameters of 1.50 and 1.17 mm, respectively, and filled with 2% Pontamine Sky Blue in 2 M NaCl. The electrodes were broken under microscope to yield an impedance of 2-4 MΩ at 135 Hz and then slowly lowered into a hole drilled in the skull above the VTA (3.2±0.3 mm anterior of the interaural line and 0.7±0.2 mm lateral to the midline by using a hydraulic microdrive. Extracellular electrical activity was amplified, filtered (band pass 0.3-3 kHz), discriminated and monitored on an oscilloscope and an audiomonitor. Discriminated spikes were fed via a CED 1401 interface to a computer running CED Spike 2 software. After the experiment the recording site was marked by iontophoresis of Pontamine Sky Blue into the tissue. The rat was killed with an overdose of anesthetic, and the brain was removed and placed in 25% sucrose 10% paraformaldehyde solution. Sections of the VTA were cut (50 μM) and stained with Neutral Red and the recording sites were verified by light microscopy.
In vitro studies of facilitation of NMDA-induced currents in pyramidal cells of the medial prefrontal cortex were conducted as described by Jardemark et al. (Int J Neuropsychopharmacol. 8: 157-162, 2005). Male Sprague-Dawley rats housed under standard laboratory conditions were used. Brain slices were prepared in the following manner: Rats were decapitated under halothane anaesthesia and the brains were rapidly removed and cooled in ice-cold Ringer's solution. The brains were then cut coronally in order to produce 450 μm slices. The brain slices were kept submerged in aerated Ringer's solution at room temperature for at least 1 hour to allow for recovery. Subsequently a single slice containing mPFC was then transferred to a recording chamber (320C), in which it was held submerged in-between two nylon nets. The chamber was continuously perfused by aerated Ringer's solution at a flow rate of 2 ml/min. Standard intracellular and single-electrode voltage-clamp techniques were used to record pyramidal cells in layers V and VI of the mPFC in slice preparations as described previously. Briefly, electrodes were pulled from borosilicate glass capillaries by using a horizontal electrode puller. Recording electrodes were filled with 2 M Potassium Acetate (the tip resistance was between 20 and 160 MΩ) and used for recording the mPFC neurons with an Axoclamp 2A amplifier. Single electrode voltage-clamp (holding potential - 60 mV) was performed in the discontinuous mode with a sampling rate of 5-6.2 kHz. The voltage recordings were acquired using a digital/analogue sampling and acquisition software. During the voltage-clamp recordings of the NMDA-evoked currents tetrodotoxin (TTX; 0,5 μM to block the action potentials), glycine (1 μM,to enhance the NMDA-induced responses) bicucculine (5 μM,to block the γ- aminobutyric acid type A (GABAA) responses) were routinely included in Ringer's solution. NMDA (5-25 μM was also applied via bath perfusion of Ringer's solution to induce inward currents. The effects of the drugs or drug combinations on the NMDA-induced currents were calculated by dividing the NMDA-induced currents after the bath application of the drugs by the control NMDA-induced currents. The results shown in the figure are presented as mean ± S.E.M.
Description of the results: Figure 1 describes the effect of citalopram and each of its enantiomers on firing rate of dopamine cells in the VTA. It is shown that citalopram at the tested doses (0-1280 μg/kg) does not increase the firing rate. On the other hand escitalopram elevates firing rate statistically significant at 320 μg/kg and this effect appears to be maintained at the higher dose (640 μg/kg). Furthermore it is shown that the firing rate is unaffected by R-citalopram and that the effect of escitalopram (320 μg/kg) can be blocked by pre-treatment with 320 μg/kg of R-citalopram, thus further substantiating that this effect is specific to escitalopram.
Figure 2 describes the effect of citalopram and each of its enantiomers on burst firing of the dopaminergic cells recorded in the in the VTA. It was shown that escitalopram increases burst firing statistically significant dose-dependently at doses equal to and above 160 μg/kg. At the highest dose tested (640 μg/kg) escitalopram causes a burst difference of about 20%. Citalopram also appear to increase burst firing, allthough this only reaches significance at the 640 μg/kg dose, and the maximal response appears to be approximately 10% burst difference. Further it is shown that R- citalopram alone has no effect on burst firing and that R-citalopram (320μg/kg) significantly inhibits the effect of escitalopram (320μg/kg).
Figure 3 describes the effect of risperidone (atypical antipsychotic), citalopram, escitalopram and reboxetine (NRI) on NMDA-induced currents in pyramidal cells of the prefrontal cortex. It has previously been shown that atypical antipsychotics increase NMDA-induced currents in this preparation. This is examplified by risperidone. It is shown that reboxetine (NRI) but not citalopram (SSRI), nor fluoxetine (data not shown) increases NMDA-induced currents. Surprisingly escitalopram facilitates the NMDA-induced currents to similar extent as the risperidone and reboxetine. It is furthermore shown that this effect is likely mediated through the dopamine Dl receptor as a dopamine Dl receptor antagonist (SCH 23390) reverses the effect of escitalopram.

Claims

Claims
1. Use of escitalopram or a pharmaceutically acceptable salt thereof for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
2. The use according to claim 1 wherein the condition is associated with schizophrenia.
3. The use according to claim 1 wherein the condition is associated with Parkinson's Disease.
4. The use according to claim 1 wherein the condition is associated with dementia, such as AIDS dementia.
5. The use according to claim 1 wherein the condition is associated with an anxiety disorder.
6. The use according to claim 1 wherein the condition is associated with age associated memory impairment.
7. The use according to claim 1 wherein the condition is associated with depression, including major depression, in particular in elderly.
8. The use according to claim 1 wherein the condition is associated with the use of benzodiazepines.
9. The use according to claim 1 wherein the condition is associated with the use of tricyclic antidepressants.
10. The use according to claim 1 wherein the condition is associated with Alzheimer's Disease.
11. The use according to claim 1 wherein the condition is associated with attention deficit hyperactivity disorder (ADHD).
12. The use according to claim 1 wherein the condition is associated with posttraumatic stress disorder (PTSD).
13. The use according to any of the preceding claims wherein the medicament is for administration as a unit dose.
14. The use according to claim 13 wherein the unit dose is containing escitalopram in an amount from 1.0 mg to 50 mg, more preferred 5 mg/day to 20 mg/day, most preferably 10 mg.
15. The use according to claim 13 or 14 wherein the unit dose is given once daily.
16. The use according to claim 15 wherein the daily doses are, 5, 10 or 20 mg.
17. Use of escitalopram or a pharmaceutically acceptable salt thereof in combination with one or more antipsychotic compounds for the preparation of a medicament for improving cognition in a condition where the cognitive processes are diminished.
18. The use according to claim 17 wherein the condition is associated with schizophrenia.
19. The use according to claim 17 wherein the condition is associated with Parkinson's Disease.
20. The use according to claim 17 wherein the condition is associated with dementia, such as AIDS dementia.
21. The use according to claim 17 wherein the condition is associated with an anxiety disorder.
22. The use according to claim 17 wherein the condition is associated with age associated memory impairment.
23. The use according to claim 17 wherein the condition is associated with depression, including major depression, in particular in elderly.
24. The use according to claim 17 wherein the condition is associated with the use of benzodiazepines.
25. The use according to claim 17 wherein the condition is associated with the use of tricyclic antidepressants.
26. The use according to claim 17 wherein the condition is associated with Alzheimer's Disease.
27. The use according to claim 17 wherein the condition is associated with attention deficit hyperactivity disorder (ADHD).
28. The use according to claim 17 wherein the condition is associated with posttraumatic stress disorder (PTSD).
29. The use according to any of the claims 17-28 wherein the antipsychotic agent is an agent approved for the treatment of a psychotic condition.
30. The use according to any of the claims 17-28 wherein the antipsychotic compound is selected from the list of Asenapine, Blonanserin, Iloperidone, Paliperidone, Bifeprunox, Lurasidone, Ocaperidone, Talnetant, ACP 104, SLV 310, ACR 16, YKP 1358, GW 773812, RGH 188, SLV 314, Y-931, BL 1020, Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Triflupromazine, Cyamemazine, Chlorproethazine, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Haloperidol, Trifluperidol, Melperone, Moperone, Pipamperone, Bromperidol, Benperidol, Droperidol, Fluanisone, Oxypertine, Molindone, Sertindole, Ziprasidone,
Flupentixol, Clopenthixol, Chlorprothixene, Tiotixene, Zuclopenthixol, Fluspirilene, Pimozide, Penfluridol, Loxapine, Clozapine, Olanzapine, Quetiapine, Sulpiride, Sultopride, Tiapride, Remoxipride, Amisulpride, Veralipride, Levosulpiride, Prothipendyl, Risperidone, Clotiapine, Mosapramine, Zotepine and Aripiprazole.
31. Use of escitalopram or a pharmaceutically acceptable salt thereof for the preparation of a medicament to be used in the adjunct treatment with an antipsychotic agent for improving cognition in a condition where the cognitive processes are diminished.
32. The use according to claim 31 wherein the condition is associated with schizophrenia.
33. The use according to claim 31 wherein the condition is associated with Parkinson's Disease.
34. The use according to claim 31 wherein the condition is associated with dementia, such as AIDS dementia.
35. The use according to claim 31 wherein the condition is associated with an anxiety disorder.
36. The use according to claim 31 wherein the condition is associated with age associated memory impairment.
37. The use according to claim 31 wherein the condition is associated with depression, including major depression, in particular in elderly.
38. The use according to claim 31 wherein the condition is associated with the use of benzodiazepines.
39. The use according to claim 31 wherein the condition is associated with the use of tricyclic antidepressants.
40. The use according to claim 31 wherein the condition is associated with Alzheimer's Disease.
41. The use according to claim 31 wherein the condition is associated with attention deficit hyperactivity disorder (ADHD).
42. The use according to claim 31 wherein the condition is associated with posttraumatic stress disorder (PTSD).
43. The use according to any of the claims 31-42 wherein the antipsychotic agent is an agent approved for the treatment of a psychotic condition.
44. The use according to any of the claims 31-42 wherein the antipsychotic agent is selected from the list of Asenapine, Blonanserin, Iloperidone, Paliperidone, Bifeprunox, Lurasidone, Ocaperidone, Talnetant, ACP 104, SLV 310, ACR 16, YKP 1358, GW 773812, RGH 188, SLV 314, Y-931, BL 1020, Chlorpromazine, Levomepromazine, Promazine, Acepromazine, Triflupromazine, Cyamemazine, Chlorproethazine, Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine,
Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine, Periciazine, Thioridazine, Mesoridazine, Pipotiazine, Haloperidol, Trifluperidol, Melperone, Moperone, Pipamperone, Bromperidol, Benperidol, Droperidol, Fluanisone, Oxypertine, Molindone, Sertindole, Ziprasidone, Flupentixol, Clopenthixol, Chlorprothixene, Tiotixene, Zuclopenthixol,
Fluspirilene, Pimozide, Penfluridol, Loxapine, Clozapine, Olanzapine, Quetiapine, Sulpiride, Sultopride, Tiapride, Remoxipride, Amisulpride, Veralipride, Levosulpiride, Prothipendyl, Risperidone, Clotiapine, Mosapramine, Zotepine and Aripiprazole.
45. A pharmaceutical composition comprising escitalopram or a pharmaceutically acceptable salt thereof and one or more antipsychotic compounds for improving cognition in a condition where the cognitive processes are diminished.
46. A method of improving cognition in a condition where the cognitive processes are diminished comprising administering escitalopram or a pharmaceutically acceptable salt thereof.
47. The method according to claim 46 wherein the condition is associated with schizophrenia.
48. The method according to claim 46 wherein the condition is associated with Parkinson's Disease.
49. The method according to claim 46 wherein the condition is associated with dementia, such as AIDS dementia.
50. The method according to claim 46 wherein the condition is associated with an anxiety disorder.
51. The method according to claim 46 wherein the condition is associated with age associated memory impairment.
52. The method according to claim 46 wherein the condition is associated with depression, including major depression, in particular in elderly.
53. The method according to claim 46 wherein the condition is associated with the use of benzodiazepines.
54. The method according to claim 46 wherein the condition is associated with the use of tricyclic antidepressants.
55. The method according to claim 46 wherein the condition is associated with Alzheimer's Disease.
56. The method according to claim 46 wherein the condition is associated with attention deficit hyperactivity disorder (ADHD).
57. The method according to claim 46 wherein the condition is associated with posttraumatic stress disorder (PTSD).
58. Use of escitalopram for the preparation of a medicament for the treatment of schizophrenia wherein the negative and cognitive symptoms are improved.
59. The use according to claim 58 wherein the medicament is for administration as a unit dose.
60. The use according to claim 59 wherein the unit dose is containing escitalopram in an amount from 1.0 mg to 50 mg, more preferred 5 mg/day to 20 mg/day, most preferably 10 mg.
61. The use according to claim 59 or 60 wherein the unit dose is given once daily.
62. The use according to claim 61 wherein the daily doses are, 5, 10 or 20 mg.
63. Use of escitalopram for the preparation of a medicament for the treatment of attention deficit hyperactivity disorder (ADHD).
64. The use according to claim 63 wherein the medicament is for administration as a unit dose.
65. The use according to claim 64 wherein the unit dose is containing escitalopram in an amount from 1.0 mg to 50 mg, more preferred 5 mg/day to 20 mg/day, most preferably 10 mg.
66. The use according to claim 64 or 65 wherein the unit dose is given once daily.
67. The use according to claim 66 wherein the daily doses are, 5, 10 or 20 mg.
68. Use of escitalopram for the preparation of a medicament useful in facilitating psychotherapy, cognitive behavioural therapy and exposure -based therapy.
69. The use according to claim 68 wherein the medicament is for administration as a unit dose.
70. The use according to claim 69 wherein the unit dose is containing escitalopram in an amount from 1.0 mg to 50 mg, more preferred 5 mg/day to 20 mg/day, most preferably 10 mg.
71. The use according to claim 69 or 70 wherein the unit dose is given once daily.
72. The use according to claim 71 wherein the daily doses are, 5, 10 or 20 mg.
PCT/DK2007/050050 2006-05-02 2007-04-30 Use of escitalopram for improving cognition WO2007124757A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002651002A CA2651002A1 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition
MX2008013911A MX2008013911A (en) 2006-05-02 2007-04-30 New uses of escitalopram.
EA200870491A EA200870491A1 (en) 2006-05-02 2007-04-30 NEW USE OF ESCITAL PREMA
BRPI0710230-5A BRPI0710230A2 (en) 2006-05-02 2007-04-30 use of escitalopram or a pharmaceutically acceptable salt of the same use of escitalopram or a pharmaceutically acceptable salt thereof in combination with one or more antipsychotic compounds, pharmaceutical composition, method for improving cognition in a condition where the cognitive process is impaired, and use of escitalopram
AU2007245983A AU2007245983A1 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition
EP07722705A EP2026793A2 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition
JP2009508134A JP2009535367A (en) 2006-05-02 2007-04-30 Use of escitalopram to improve cognition
IL194628A IL194628A0 (en) 2006-05-02 2008-10-07 Use of escitalopram for improving cognition
ZA2008/08632A ZA200808632B (en) 2006-05-02 2008-10-09 Use of escitalopram for improving cognition
NO20085009A NO20085009L (en) 2006-05-02 2008-12-02 New uses of escitalopram

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600621 2006-05-02
DKPA200600621 2006-05-02

Publications (2)

Publication Number Publication Date
WO2007124757A2 true WO2007124757A2 (en) 2007-11-08
WO2007124757A3 WO2007124757A3 (en) 2008-07-24

Family

ID=38134951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2007/050050 WO2007124757A2 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition

Country Status (15)

Country Link
EP (1) EP2026793A2 (en)
JP (1) JP2009535367A (en)
KR (1) KR20090009820A (en)
CN (1) CN101426494A (en)
AR (1) AR060732A1 (en)
AU (1) AU2007245983A1 (en)
BR (1) BRPI0710230A2 (en)
CA (1) CA2651002A1 (en)
EA (1) EA200870491A1 (en)
IL (1) IL194628A0 (en)
MX (1) MX2008013911A (en)
NO (1) NO20085009L (en)
TW (1) TW200812993A (en)
WO (1) WO2007124757A2 (en)
ZA (1) ZA200808632B (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
WO2012063513A1 (en) * 2010-11-08 2012-05-18 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
US8552000B2 (en) 2003-06-23 2013-10-08 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
AU2008283989B2 (en) * 2007-08-03 2013-12-05 Richter Gedeon Nyrt. Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands.
US8835438B2 (en) 2004-02-20 2014-09-16 Sumitomo Dainippon Pharma Co., Ltd. Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone
US9174975B2 (en) 2002-08-22 2015-11-03 Sumitomo Dainippon Pharma Co., Ltd Remedy for integration dysfunction syndrome
EP3069718A1 (en) * 2015-03-17 2016-09-21 Universidade do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
KR102051624B1 (en) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 Pharmaceutical composition for treatment of neurodegenerative brain disease comprising triflupromazine or pharmacurically acceptable salt thereof as an active ingredient
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109464436A (en) * 2019-01-10 2019-03-15 高智玉 Citalopram or escitalopram combine the application in the compound preparation of preparation treatment phrenoblabia class disease with Quetiapine respectively

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474580A2 (en) * 1990-09-06 1992-03-11 H. Lundbeck A/S Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders
WO2000015219A1 (en) * 1998-09-16 2000-03-23 Astrazeneca Ab A new composition
WO2000015220A1 (en) * 1998-09-16 2000-03-23 Astrazeneca Ab A new composition
WO2002043764A1 (en) * 2000-12-01 2002-06-06 Be Able, Llc Behavior chemotherapy
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
WO2003041563A2 (en) * 2001-11-13 2003-05-22 Be Able, Llc Neurotransmitter balance chemotherapy
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2004056791A1 (en) * 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
WO2005023243A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and loxapine
WO2007048080A2 (en) * 2005-10-14 2007-04-26 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
WO2007053796A2 (en) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
WO2007070840A2 (en) * 2005-12-14 2007-06-21 H. Lundbck A/S. Modified and pulsatile release pharmaceutical formulations of escitalopram

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474580A2 (en) * 1990-09-06 1992-03-11 H. Lundbeck A/S Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders
WO2000015219A1 (en) * 1998-09-16 2000-03-23 Astrazeneca Ab A new composition
WO2000015220A1 (en) * 1998-09-16 2000-03-23 Astrazeneca Ab A new composition
WO2002043764A1 (en) * 2000-12-01 2002-06-06 Be Able, Llc Behavior chemotherapy
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
WO2003041563A2 (en) * 2001-11-13 2003-05-22 Be Able, Llc Neurotransmitter balance chemotherapy
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2004056791A1 (en) * 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
WO2005023243A1 (en) * 2003-09-04 2005-03-17 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and loxapine
WO2007048080A2 (en) * 2005-10-14 2007-04-26 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
WO2007053796A2 (en) * 2005-10-14 2007-05-10 Forest Laboratories, Inc. Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
WO2007070840A2 (en) * 2005-12-14 2007-06-21 H. Lundbck A/S. Modified and pulsatile release pharmaceutical formulations of escitalopram

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANGELONE S M ET AL: "Effects of fluvoxamine and citalopram in maintaining abstinence in a sample of Italian detoxified alcoholics." ALCOHOL AND ALCOHOLISM (OXFORD, OXFORDSHIRE) 1998 MAR-APR, vol. 33, no. 2, March 1998 (1998-03), pages 151-156, XP002481209 ISSN: 0735-0414 *
BAUMANN PIERRE ET AL: "Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram." EUROPEAN NEUROPSYCHOPHARMACOLOGY : THE JOURNAL OF THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY OCT 2002, vol. 12, no. 5, October 2002 (2002-10), pages 433-444, XP002481210 ISSN: 0924-977X *
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 2005 (2005-06), FRIEDMAN JOSEPH I ET AL: "The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia" XP002481217 Database accession no. PREV200510070715 cited in the application & JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, vol. 25, no. 3, June 2005 (2005-06), pages 237-242, ISSN: 0271-0749 *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DAVIDS, EUGEN ET AL: "Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats" XP002481212 retrieved from STN Database accession no. 2002:435038 & JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS , 301(3), 1097-1102 CODEN: JPETAB; ISSN: 0022-3565, 2002, *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FEDOTOVA, YU. O. ET AL: "Cypramil correction of passive avoidance performance in ovariectomized female rats" XP002481216 retrieved from STN Database accession no. 2003:207883 & EKSPERIMENTAL'NAYA I KLINICHESKAYA FARMAKOLOGIYA , 66(1), 8-11 CODEN: EKFAE9; ISSN: 0869-2092, 2003, *
DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2003, SVESTKA J: "Escitalopram - The selective stereoisomer of citalopram" XP002481218 Database accession no. EMB-2003157849 & PSYCHIATRIE 2003 CZ, vol. 7, no. 1, 2003, pages 38-45, ISSN: 1211-7579 *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1999 (1999-12), CALANDRA C ET AL: "The use of citalopram in an integrated approach to the treatment of eating disorders: an open study." XP002481215 Database accession no. NLM10728184 & EATING AND WEIGHT DISORDERS : EWD DEC 1999, vol. 4, no. 4, December 1999 (1999-12), pages 207-210, ISSN: 1124-4909 *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2004 (2004-02), STEIN MICHAEL D ET AL: "Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users." XP002481213 Database accession no. NLM14757591 & ARCHIVES OF GENERAL PSYCHIATRY FEB 2004, vol. 61, no. 2, February 2004 (2004-02), pages 152-159, ISSN: 0003-990X *
DATABASE MEDLINE [Online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; October 2001 (2001-10), ALEXOPOULOS G S ET AL: "The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients." XP002481214 Database accession no. NLM17205639 & POSTGRADUATE MEDICINE OCT 2001, vol. Spec No Pharmacotherapy, October 2001 (2001-10), pages 1-86, ISSN: 0032-5481 *
MONTGOMERY S A ET AL: "ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004." EUROPEAN NEUROPSYCHOPHARMACOLOGY : THE JOURNAL OF THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY JAN 2007, vol. 17, no. 1, January 2007 (2007-01), pages 70-77, XP002481211 ISSN: 0924-977X *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9815827B2 (en) 2002-08-22 2017-11-14 Sumitomo Dainippon Pharma Co., Ltd. Agent for treatment of schizophrenia
US9174975B2 (en) 2002-08-22 2015-11-03 Sumitomo Dainippon Pharma Co., Ltd Remedy for integration dysfunction syndrome
US8552000B2 (en) 2003-06-23 2013-10-08 Dainippon Sumitomo Pharma Co., Ltd. Therapeutic agent for senile dementia
US8835438B2 (en) 2004-02-20 2014-09-16 Sumitomo Dainippon Pharma Co., Ltd. Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone
AU2008283989B2 (en) * 2007-08-03 2013-12-05 Richter Gedeon Nyrt. Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands.
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
US9827242B2 (en) 2010-11-08 2017-11-28 Sumitomo Dainippon Pharma Co., Ltd. Method of treatment for mental disorders
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
US9259423B2 (en) 2010-11-08 2016-02-16 Sumitomo Dainippon Pharma Co., Ltd. Method of treatment for mental disorders
US10098875B2 (en) 2010-11-08 2018-10-16 Sumitomo Dainippon Pharma Co., Ltd. Method of treatment for mental disorders
WO2012063513A1 (en) * 2010-11-08 2012-05-18 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP3069718A1 (en) * 2015-03-17 2016-09-21 Universidade do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
WO2016147146A1 (en) * 2015-03-17 2016-09-22 Universidade Do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
US11033526B2 (en) 2015-03-17 2021-06-15 Universidade Do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
US10898449B2 (en) 2016-12-20 2021-01-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US10980753B2 (en) 2016-12-20 2021-04-20 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
KR102051624B1 (en) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 Pharmaceutical composition for treatment of neurodegenerative brain disease comprising triflupromazine or pharmacurically acceptable salt thereof as an active ingredient

Also Published As

Publication number Publication date
CA2651002A1 (en) 2007-11-08
ZA200808632B (en) 2009-12-30
CN101426494A (en) 2009-05-06
KR20090009820A (en) 2009-01-23
BRPI0710230A2 (en) 2011-08-02
TW200812993A (en) 2008-03-16
AU2007245983A1 (en) 2007-11-08
IL194628A0 (en) 2009-08-03
EP2026793A2 (en) 2009-02-25
EA200870491A1 (en) 2009-04-28
WO2007124757A3 (en) 2008-07-24
NO20085009L (en) 2008-12-16
JP2009535367A (en) 2009-10-01
AR060732A1 (en) 2008-07-10
MX2008013911A (en) 2008-11-12

Similar Documents

Publication Publication Date Title
EP2026793A2 (en) Use of escitalopram for improving cognition
ES2642873T3 (en) Compositions comprising nicotinic agonists and methods for their use
AT10974U1 (en) USE OF ENANTIOMER-PURE ESCITALOPRAM
US20070259952A1 (en) Uses of escitalopram
JP3756193B2 (en) Method for treating and diagnosing sleep disordered breathing and means for implementing this method
EA003142B1 (en) Pharmaceutical composition with an antidepressive effect use thereof and method for treating
DE69833645T2 (en) NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTICS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDER
DE69926804T2 (en) DEVICES FOR TREATMENT AND DIAGNOSIS OF RESTLESS LEG SYNDROME
JP6676062B2 (en) Methods for treating cognitive decline
JPS59193821A (en) Use of fluoxetin as antianxiety
JP7429942B2 (en) Enantiomers of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (ANAVEX2-73) and their use in the treatment of Alzheimer type and other disorders regulated by sigma 1 receptors
DE60111025T2 (en) Use of topiramate for the treatment and diagnosis of respiratory disorders during sleep and means for performing the treatment and diagnosis
JPH037218A (en) Medicinal composition
EP1576985A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
TWI583679B (en) Methods of use of cyclic amide derivatives to treat schizophrenia
WO1992018005A1 (en) Method of treating trichotillomania and onychophagia
TW201141468A (en) Neramexane for the treatment or prevention of inner ear disorders
DE60125062T2 (en) Quetiapine for the treatment of dyskinesia in non-psychotic patients
JP6084931B2 (en) Neramexane for the treatment or prevention of tinnitus associated with stress or acute hearing loss
CA2461248C (en) Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
DE60305018T2 (en) CITALOPRAM FOR THE TREATMENT OF BLOOD HIGH PRESSURE
WO2007007133A2 (en) Composition for treatment of psychosis
WO2019126204A1 (en) Methods and compositions for the treatment of traumatic brain injury (tbi) and related disorders
JP5042425B2 (en) Tramadol for the treatment of functional gastrointestinal diseases
JP2000514441A (en) Use of 3,4-diphenylchroman for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07722705

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 571785

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12008502259

Country of ref document: PH

Ref document number: 194628

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020087025797

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200780014675.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/013911

Country of ref document: MX

Ref document number: 2008101785

Country of ref document: EG

Ref document number: 2007245983

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2651002

Country of ref document: CA

Ref document number: 2009508134

Country of ref document: JP

Ref document number: 08116966

Country of ref document: CO

Ref document number: 5930/CHENP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007245983

Country of ref document: AU

Date of ref document: 20070430

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007722705

Country of ref document: EP

Ref document number: 200870491

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0710230

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081020